A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer Germany

[1]  H. Sørensen,et al.  Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study , 2021, Cancer Epidemiology, Biomarkers & Prevention.

[2]  H. Adami,et al.  Ranitidine Use and Risk of Upper Gastrointestinal Cancers , 2021, Cancer Epidemiology, Biomarkers & Prevention.

[3]  M. Sandy,et al.  Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications , 2021, International journal of environmental research and public health.

[4]  K. Broich,et al.  N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer-A Longitudinal Cohort Study Based on German Health Insurance Data. , 2021, Deutsches Arzteblatt international.

[5]  C. Cardwell,et al.  Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study , 2021, The American journal of gastroenterology.

[6]  B. Tuesuwan,et al.  Nitrosamine contamination in pharmaceuticals: threat, impact, and control. , 2021, Journal of pharmaceutical sciences.

[7]  B. Engelward.  Implications of an epidemiological study showing an association between in utero NDMA exposure and childhood cancer , 2021, Environmental and molecular mutagenesis.

[8]  M. Du,et al.  Ranitidine Use and Cancer Risk: Results from UK Biobank. , 2020, Gastroenterology.

[9]  S. Atal,et al.  Understanding the molecular–pharmaceutical basis of sartan recalls focusing on valsartan , 2020, Global cardiology science & practice.

[10]  U. Laufs,et al.  Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany , 2020, Journal of Human Hypertension.

[11]  M. Maliepaard,et al.  Pharmacokinetics and Generic Drug Switching: A Regulator’s View , 2020, Clinical Pharmacokinetics.

[12]  J. Tamargo,et al.  Low-quality of some generic medicinal products represents a matter for growing concern. , 2020, European heart journal. Cardiovascular pharmacotherapy.

[13]  D. Elder,et al.  Short commentary on NDMA (N‐nitrosodimethylamine) contamination of valsartan products , 2019, Regulatory toxicology and pharmacology : RTP.

[14]  W. Rathmann,et al.  Basic characteristics and representativeness of the German Disease Analyzer database
. , 2018, International journal of clinical pharmacology and therapeutics.

[15]  Jesper Hallas,et al.  Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study , 2018, British Medical Journal.

[16]  A. Barbieri,et al.  Dissecting the mechanisms and molecules underlying the potential carcinogenicity of red and processed meat in colorectal cancer (CRC): an overview on the current state of knowledge , 2018, Infectious Agents and Cancer.

[17]  A. Gasparrini,et al.  Interrupted time series regression for the evaluation of public health interventions: a tutorial , 2016, International journal of epidemiology.

[18]  F. Alla,et al.  Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study , 2015, Gut.

[19]  K. Kostev,et al.  Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. , 2009, International journal of clinical pharmacology and therapeutics.

[20]  A K Wagner,et al.  Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.

[21]  D Taeger,et al.  Exposure to high concentrations of nitrosamines and cancer mortality among a cohort of rubber workers , 2000, Occupational and environmental medicine.

[22]  D. Martin,et al.  Exact Estimates for a Rate Ratio , 1996, Epidemiology.

[23]  D. Martin,et al.  An efficient program for computing conditional maximum likelihood estimates and exact confidence limits for a common odds ratio. , 1991, Epidemiology.

[24]  V. Craddock.  Toxicology: Nitrosamines and human cancer: proof of an association? , 1983, Nature.